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Background
The avian poxvirus ALVAC constitutes the backbone of the
recombinant HIV vaccine tested in the phase III RV144
trial in Thailand. ALVAC HIV-1 vaccine candidates have
been tested in several animal models. Protection from
infection was observed in chimpanzees whereby, one of
two animals was protected (1); in adult animals 2 of 5 vac-
cinated rhesus macaques (2) and 4 of 10 of cynomolgus
macaques (3) remained virus free; in neonate macaques
10 of 16 animals remained virus free following repeated
oral exposure to low doses of SIVmac251 (4). Vaccination
with the same vaccine reduced plasma virus in vaccinated
neonates that became infected and in adult vaccinated
macaques (4,5). ALVAC-based vaccines have also pro-
tected 5 of 18 vaccinated macaques from SHIVKU2 infec-
tions (6).
Methods
Differences in target cells, age, and MHC class I combined
with differences in the tropism and dose of the viral chal-
lenge stock, may account for the various degree of protec-
tion observed in the different studies.
Results
The results of the challenge exposure to SIVmac251 will
be available in October of 2009 and will be compared to
the results of the RV144 trial.
Conclusion
Because we believe that the results of the RV144 trial in
humans will help to validate animal models of AIDS, we
initiated a study in macaques that mimics the RV144 in
humans.The vaccinated adult macaques developed
mucosal effector responses to SIVmac251 and will be
challenged by the mucosal route, either with a high dose
or low repeated doses of SIVmac251.
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